SuperSaturated Oxygen Therapy for Heart Attack

(SSCORE Trial)

This trial examines the effectiveness of SuperSaturated Oxygen (SSO2) Therapy compared to the usual treatment for heart attacks, specifically those involving the heart's left front artery. The researchers aim to determine if SSO2 can reduce heart failure and healthcare costs more effectively than the standard procedure, percutaneous coronary intervention (PCI). Participants must have experienced a heart attack in the left front artery and received PCI treatment within 6 hours of symptom onset. This study will help determine if SSO2 Therapy offers additional benefits in real-world settings. As a Phase 3 trial, it represents the final step before FDA approval, providing participants an opportunity to contribute to potentially groundbreaking treatment advancements.

Studies have shown that SuperSaturated Oxygen (SSO2) Therapy is generally safe for patients who have had heart attacks. Research indicates that SSO2 Therapy does not increase the risk of major heart problems compared to standard treatments. Nearly 800 patients participated in various studies, confirming its safety. This therapy has even been linked to better outcomes, such as fewer deaths and heart issues within a year after treatment. Overall, SSO2 Therapy appears promising with a good safety record for people recovering from heart attacks.¹²³⁴⁵

Researchers are excited about supersaturated oxygen (SSO2) therapy because it offers a unique approach to treating heart conditions, particularly following a heart attack. Unlike traditional treatments that mainly aim to restore blood flow and reduce clotting, SSO2 therapy works by delivering a higher concentration of oxygen directly to damaged heart tissue. This heightened oxygen delivery can potentially reduce tissue damage and improve heart function more effectively. By targeting the heart tissue in this novel way, SSO2 therapy might offer quicker recovery and better outcomes for patients compared to standard care options like medication and angioplasty.

In this trial, participants will join one of two groups: one group will receive SuperSaturated Oxygen (SSO2) Therapy, while the other will serve as a control group and will not receive SSO2. Studies have shown that SSO2 Therapy can benefit individuals who have experienced heart attacks, particularly those affecting the front part of the heart. Research indicates that SSO2 Therapy reduces heart tissue damage after a heart attack. This therapy involves adding high levels of oxygen to the blood, aiding heart healing and potentially decreasing the risk of death and new heart problems. These findings suggest that SSO2 Therapy could be a promising option to improve recovery and reduce heart failure in heart attack patients.²⁵⁶⁷⁸